Fernando Valiente-Echeverría
Fernando Valiente-Echeverría is an expert in Infectiology at Hospital Clínico de la Universidad de Chile (Chile). Fernando Valiente-Echeverría has authored 89 publications, the most recent in 2026. SLR score: 250 (community average: 125). How the SLR is computed.
LeadR Profile
Infectiology
Subspecialties: Immunology - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 2012 - 2026
Number : 89
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| NF-κB-dependent and independent inflammatory responses during acute HIV-1 infection in a model of human microglia. PMID 42666215 — cytokines, microglia, hiv-1, hiv, infections | Front Immunol | 2026 | 0 |
| Transcriptomic Profiling Identifies TALAM1 and LINC00702 as HIV-1-Responsive lncRNAs in Microglia. PMID 41977450 — microglia, cells, hiv-1, macrophages, hiv, cell line, infections | Int J Mol Sci | 2026 | 0 |
| Activation of IRE1 Endonuclease Activity Regulates Zika Virus Replication and Antiviral Response During Infection in Human Microglia. PMID 41157563 — microglia, cells, zika virus, stress, physiological, virus replication, viruses, interferon type i, immunity, innate, endonucleases, antiviral agents, infections | Viruses | 2025 | 0 |
| Impact of seasonal variation on the oral and nasopharyngeal microbiome in school-aged children: the school MicroBE initiative. PMID 40778780 — genes, rrna, disease outbreaks, schools, public health, aged, microbiological phenomena, cluster analysis, environment, microbiota, child, oral microbiome | mSystems | 2025 | 2 |
| Convalescent plasma therapy and long-term SARS-COV-2 antiviral immune response in a prospective cohort of patients with COVID-19. PMID 40740192 — cells, sars-cov-2, covid-19, immunity, therapeutics, severe acute respiratory syndrome-related coronavirus, outpatients, antiviral agents, plasma | Curr Res Microb Sci | 2025 | 0 |
LeadR Networks
Main global connection map